8,108 DexCom, Inc. $DXCM Shares Acquired by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 8.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 101,020 shares of the medical device company’s stock after purchasing an additional 8,108 shares during the quarter. Rakuten Investment Management Inc.’s holdings in DexCom were worth $8,752,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of the stock. Ascentis Independent Advisors purchased a new position in DexCom in the 1st quarter worth approximately $25,000. Latitude Advisors LLC bought a new position in shares of DexCom in the 3rd quarter worth $32,000. Hilton Head Capital Partners LLC raised its position in shares of DexCom by 242.3% during the 3rd quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company’s stock valued at $33,000 after buying an additional 269 shares in the last quarter. Wellington Grp LLC raised its position in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after buying an additional 475 shares in the last quarter. Finally, Elevation Wealth Partners LLC raised its position in shares of DexCom by 61.0% during the 3rd quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock valued at $35,000 after buying an additional 152 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Price Performance

Shares of DexCom stock opened at $84.46 on Friday. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $92.59. The stock has a market capitalization of $31.50 billion, a price-to-earnings ratio of 33.14, a price-to-earnings-growth ratio of 1.46 and a beta of 1.45. The company has a fifty day moving average of $85.40 and a 200-day moving average of $74.96. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.40 and a current ratio of 1.74.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.68 by $0.05. The company had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.61 EPS. Equities research analysts expect that DexCom, Inc. will post 2.68 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Michael Brown sold 1,700 shares of the business’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $85.48, for a total value of $145,316.00. Following the completion of the sale, the executive vice president owned 98,185 shares of the company’s stock, valued at approximately $8,392,853.80. The trade was a 1.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total value of $549,537.56. Following the completion of the sale, the director directly owned 29,293 shares of the company’s stock, valued at approximately $2,461,783.72. This trade represents a 18.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 22,822 shares of company stock valued at $1,920,193. Corporate insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Leerink Partners dropped their price objective on shares of DexCom from $94.00 to $87.00 and set an “outperform” rating for the company in a report on Monday, October 26th. Barclays increased their target price on DexCom from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. TD Cowen restated a “buy” rating and set a $95.00 price target on shares of DexCom in a research report on Friday, September 18th. Benchmark raised their price target on DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $105.00 price objective (up from $90.00) on shares of DexCom in a report on Thursday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $95.50.

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.